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Abstract Metallothionein (MT) has been shown to have
pro-proliferative anti-apoptotic activity and to be involved
in microenvironment remodeling. The aim of this study has
been to determine whether the changes in MT and vimentin
immunoreactivity observed in cancer and its microenviron-
ment are related to the local spread of the disease. The
immunoreactivity levels of both MT and vimentin were
evaluated together with CD56 and CD57 antigens in 49
tissue samples taken from patients with squamous cell car-
cinoma originating from the palatine tonsils and in 20 tissue
samples derived from patients with chronic tonsillitis (the
reference group). MT immunoreactivity levels were statisti-
cally significantly higher in the tissue samples from squa-
mous cell carcinoma than in those of the reference group
and also higher in the squamous cell carcinoma samples
compared with the stromal samples. Moreover, stromal
fibroblasts exhibited high vimentin and MT immunoreactiv-
ity levels. Statistically significantly higher MT immunore-
activity levels within the tumor cells were identified in
patients with the presence of lymph node metastases in
contrast to those patients without such metastases. Vimentin
was detected in both the tumor and the stromal tissue samples
and presented an interesting pattern of staining strongly
expressed within the stroma and the septal architecture of
the tumor. The number of CD56- and CD57-positive lympho-
cytes identified in tissue samples both from squamous cell
carcinoma and from the stroma was statistically significantly
lower than that in the reference group. MT expression by
tumor cells is thus associated with an aggressive phenotype
of the tumor and the ability to create metastases.
Keywords Metallothionein (MT) . Vimentin . Cancer
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Introduction
Tumor microenvironment remodeling is a response to tumor
growth and aggressiveness and seems to play a crucial role
in both local tumor spread and the process of creating
metastases (Witz 2009; Dvorak 1986; Lorusso and Ruegg
2008). Moreover, tumor microenvironment remodeling is a
complex process that includes angiogenesis, the epithelial to
mesenchymal transition and a change in the activity profile
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of various cells, such as those of the immune system and
structural cells, which, like fibroblasts, can be activated into
cancer-associated fibroblasts (CAFs). The cells of the tumor
microenvironment that are most important for the formation
of metastases are endothelial cells, tumor-associated macro-
phages and CAFs (Witz 2009; Dvorak 1986; Lorusso and
Ruegg 2008; Acevedo et al. 2007).
Metastatic tumor cells must first acquire the ability to
detach from the tumor and enter the vessels, migrate and
home toward the distant tissues forming the secondary
tumors. This ability is linked with the epithelial to mesen-
chymal transition and the process is characterized at the
molecular level by the expression of mesenchymal markers
including vimentin and N-cadherin. Vimentin is a cytoskel-
etal intermediate filament that is also expressed by CAF
(Hugo et al. 2007; Xu et al. 2006; Grunert et al. 2003).
These mesenchymal markers appear shortly before tumor
invasion and degrade the basal membrane and extracellular
matrix by means of secreted serine proteases and matrix
metalloproteinases. CAFs express both IGF (insulin-growth
factor) and HGF (hepatocyte growth factor), which stimu-
late cell survival, migration and the secretion of pro-
angiogenic factors, such as FGF-2 (fibroblast growth
factor-2), vascular endothelial growth factor and pro-
inflammatory cytokines, such as interleukin-1 (IL-1), IL-6,
IL-8 and tumor necrosis factor-α (Hugo et al. 2007; Xu et al.
2006; Grunert et al. 2003). These cells not only induce their
own migration to the tumor but also promote the survival,
proliferation and invasion of tumor cells and angiogenesis,
in addition to improving the ability of the tumor to dissem-
inate (Orimo et al. 2005; Hayward et al. 2001; De Wever
and Mareel 2005). The expression of vimentin in various
cancers has been related to poor prognostic factors, as, in
prostate cancer, vimentin is overexpressed and contributes to
its invasive and metastatic potential and, in non-small-cell lung
cancer, vimentin overexpression has been found to be an inde-
pendent prognostic factor for poor survival (Satelli and Li 2011;
de Araujo et al. 1993).
Metallothioneins (MT) are a family of low-molecular-
weight proteins that perform various important activities.
MT expression in cell cytoplasm protects against cytotox-
icity, whereas nuclear expression protects against genotox-
icity (Cherian et al. 2003; Apostolova and Cherian 2000)
and has been shown to protect against oxidative stress
(Theocharis et al. 2004). MT also has an important anti-
apoptotic and pro-proliferative activity (Klaassen et al.
1999; Shimoda et al. 2003). Sundelin et al. (1997) have
observed MT expression in cancers in which it has been
associated with both higher cell proliferation rates and fewer
positive apoptotic cells (Jayasurya et al. 2000; Sundelin et
al. 1997). Moreover, MT plays an important immunomodu-
lating role (Sundelin et al. 1997). In our previous studies,
MT has been observed in patients with head and neck cancer
and breast adenocarcinoma and has been found in the cancer
microenvironment. In salivary gland adenocarcinoma, MT
expression has been detected in both the cancer and in the
stroma in which it is represented by stromal fibroblasts
(Dutsch-Wicherek et al. 2005, 2008, 2010; Popiela et al.
2006). The tumor modifies the local anti-tumor immune
response, which creates the suppressive tumor microenvi-
ronment. The two populations of lymphocytes, namely
NKTs (natural killer-like T cells) and CD56- and CD57-
expressing cells, have an important immunoregulatory role
(Okada et al. 1995; Takii et al. 1994). CD56-positive T
lymphocytes demonstrate an effector function of cytotoxic
T cells (Satoh et al. 1996), whereas CD57-positive T lym-
phocytes demonstrate an immunoregulatory role for T-
cytotoxic lymphocytes (Kuss et al. 2004; Sallusto et al.
2004). Since the immunohistochemical method does not
allow the type of immune cells to be identified precisely,
our goal has been to determine the presence of CD56- and
CD57-positive cells responsible for the effector immune
response in pharyngeal carcinoma and its stroma.
We have previously demonstrated that MT and vimentin
are proteins involved in the remodeling of the tumor micro-
environment in salivary gland adenocarcinomas (Dutsch-
Wicherek et al. 2010). The aim of our present study has
been to determine whether the changes in MT and vimentin
expression observed in tumor microenvironment remodel-
ing in adenocarcinoma tissue samples are typical for this
histological type of tumor only or whether they are found in
the tissue of growing tumors regardless of histological type.
Materials and methods
Group of patients
For our study, we recruited patients with primary squamous
cell carcinoma originating from the palatine tonsils and
selected 49 from each of whom a tissue sample from the
carcinoma and from the tumor microenvironment were ana-
lyzed. The microenvironment or stroma of the tumor was
defined as the surrounding tissue with an area of 1 cm2 macro-
scopically and histologically free of cancer infiltration, with
the distance from the tumor front not exceeding 1 cm.
In all the patients, radical surgery of the tumor was per-
formed together with lymphadenectomy. In each case, the
patient’s consent was obtained. Additionally, approval for
the research program was granted from the Ethical Committee
of the Jagiellonian University in Krakow: KBET/90/B/2005.
All the tissue samples were histopathologically verified.
Pathological analysis with classical hematoxylin and eosin
staining techniques after fixation of the surgically removed
material in formalin was performed in the Pathology Depart-
ment of the Jagiellonian University by two experienced
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pathologists (R.T. and A.L.) who worked independently. In
detail, the tissue was fixed in a solution of 10% formalin, rinsed,
dehydrated and transferred through a progressively increasing
concentration of ethanol (from 50% to absolute alcohol) and a
series of xylenes (I–III) to molten paraffin wax. Finally, the
tissue blocks were sectioned and the sections were placed onto
glass slides. The process was mainly automated but both the
paraffin embedding and the cutting of the tissue samples into 3–
to 4-μm-thick sections were performed manually.
The characteristics of the patient group are presented in
Table 1.
Reference group
As a reference group, we chose to collect palatine tonsils that
had been removed from patients because of recurrent tonsilli-
tis. In these tissue samples, we evaluated the epithelium lining
the tonsils rather than the lymphoid tissue (Table 2).
Immunohistochemical analysis
In the present study, we aimed to analyze the immunoreac-
tivity levels of various antigens in pharyngeal squamous cell
carcinoma and its stroma. We were also interested in the
distribution of the antigen immunoreactivity throughout the
tissue of the tumor, including the tumor stroma. For this
reason, we chose the immunohistochemical method for the
present study. This is also the only method that shows the
actual architecture of the interaction between the tumor and
its stroma.
From every tumor, 3–4 tissue samples were taken
(depending on tumor size; if, for instance, the tumor was
1 cm in diameter, then it was subject to further analysis).
Every tissue sample was embedded in paraffin and formed
into a tissue block, which was then cut into sections. All the
tissue sections were further histopathologically verified and
immunohistochemistry was performed.
Two observers, working independently and having no
knowledge of the clinicopathological data, reviewed the
immunohistochemical expression of MT, vimentin and
CD56- and CD57-positive cells. Immunohistochemical
analysis was performed in the Pathology Department of
the Jagiellonian University. Sections (5 μm thick) from
each case were deparaffinized, rehydrated and rinsed in
distilled water. Endogenous peroxidase activity was
blocked by an 8-min incubation in 3% H2O2 at room
temperature. The sections were then rinsed and immersed
in a boiling citrate buffer (pH6.0) in a microwave oven
with three changes of buffer for 5 min each. Immunohisto-
chemistry was performed in each case by applying the
Envision method and a DakoAutostainer. The samples were
stained automatically, with immunohistochemical staining
being based on the antigen-antibody reaction. Microscopy
was performed by using an Axio Zeiss microscope and the
tissue sections were then evaluated under both 20× and 40×
magnification.
The following antibodies were applied: CD56, CD57
(Novocastra; dilution 1:50) Vimentin (DAKO, Denmark;
dilution 1:50) and MT (ABCAM; dilution 1:25) for
10 min at room temperature. Sections were counterstained
with hematoxylin and mounted in glycergel. As a positive
control, a tonsil specimen was taken for MT immunostain-
ing. All staining was performed identically, with only the
primary antibody being omitted as a negative control. Expres-
sion for MTand for vimentin was evaluated in entire sections,
Table 1 Characteristics of the patient group and their tumors






























Age range (average) in years 16–57 (30.41)
Men 20–53 (33.37)
Women 16–57 (27.7)
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both in the area of the tumor and in the stroma, as follows: 0,
no reactivity; +1, weak cytoplasmic staining pattern (also
granular in the paranuclear region) in up to 10% of positive
cells; +2, marked cytoplasmic (sometimes together with mem-
branous) staining in 11%–30% of the cells; +3, high expres-
sion in more than 30% of positive cells. Variable scales were
used to evaluate the amount of CD56+ and CD57+ cells semi-
quantitatively, depending on their general number in the spec-
imen and provided an average cell number per 1 hpf (high
Statistical analysis
The distribution of variables in the study groups of the
patients, as checked with the use of the Shapiro-Wilk test,
showed that each of the patients was indeed different from
normal. The statistical significance between the groups was
determined by the Kruskal-Wallis test, a one-way analysis of
variance by ranks. The Mann-Whitney U test was then used
as applicable. All statistical analyses were carried out with
the Statistica 8.0 software program. A P-value of <0.05 was
considered as indicative of statistical significance.
Results
The immunoreactivity levels of the various antigens in the
squamous cell carcinoma and stromal tissue samples were as
follows.
CD56 and CD57 immunoreactivity
CD56 antigen immunoreactivity was identified in 4% of
cells in tissue samples from squamous cell carcinoma and
in 4% of cells from the stromal samples and presented a
cytoplasmic pattern of staining. CD57 antigen immunoreac-
tivity was observed in 27.5% of cells of tissue samples from
squamous cell carcinoma and in 16% of cells from the
stromal tissue samples and also presented a cytoplasmic
pattern of staining (Fig. 1).
MT immunoreactivity
MT antigen immunoreactivity was observed in 84% of the
tissue samples from squamous cell carcinoma and in
21.7% of the stromal tissue samples and most frequently
presented a nuclear-cytoplasmic pattern of staining. The
highest MT immunoreactivity levels were observed in the
tissue samples from squamous cell carcinoma derived
from patients with the presence of lymph node metastases
Fig. 1 Immunoreactivity
(brown) of CD56 (a) and CD57
(b) antigens in squamous cell




Fig. 2 Strong MT
immunoreactivity (brown) in
squamous cell carcinoma of a
patient with lymph node
metastases. Magnification 10×
(a), 40× (b). Bars50 μm
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power field, objective magnification ×40). CD56+ and
CD57+ cells were thus estimated as follows: 0, lack of posi-
tive cells; +1, single positive cells in the specimen; +2, 2–5
positive cells per 1 hpf; +3, more than 5 positive cells/1 hpf.
(Fig. 2a, b). In the stroma, MT immunoreactivity was
observed on fibroblasts and presented a membranous-
cytoplasmic pattern of staining (Fig. 3a, b). Low MT
immunoreactivivty was seen in patients without lymph
node metastases (Fig. 4a, b).
MT immunoreactivity was also determined in the tumor
center (older part of the tumor without signs of dynamic
growth) and in the tumor front (border, the younger part of
the tumor with signs of dynamic growth). The categoriza-
tion of the central and border parts of the tumor was carried
out by means of morphological assessment. The central part
of the tumor, with a higher number of apoptotic cells, a
small number of fibroblasts and the presence of single
macrophages, presented low MT antigen immunoreactivity.
The border part of the tumor, was typified by its higher MT
antigen immunoreactivity (Fig. 5a, b). Later, Ki67 immu-
nostaining was performed in order to evaluate the rate of
proliferation in these areas. The proliferation rate in the
areas of the tumors initially defined as central parts was
significantly lower when compared with the rate in the areas
defined as borders (P<0.005).
In the reference group, MT immunoreactivity was not
uniform in the whole tissue of palatine tonsils. In the epi-
thelium, it was exclusively present within the crypts
(Fig. 5c), whereas in the lymphoid tissue, it was also ob-
served in the stromal fibroblasts (Fig. 5d).
Vimentin immunoreactivity
Strong immunoreactivity of vimentin antigen was observed
within the cancer cells in 31% of the tissue samples from
squamous cell carcinoma and within stromal fibroblasts in
28.9% of the stromal tissue samples and presented a
membranous-cytoplasmic pattern of staining (Figs. 6 and 7).
Vimentin immunoreactivity was not observed in the epithelia
of the palatine tonsils in the reference samples (not shown).
Comparison of immunoreactivity levels of antigens
analyzed in squamous cell carcinoma and stroma samples
The results obtained are presented in Table 3. Statistically
significantly higher MT and vimentin immunoreactivity
levels were observed in the tissue samples from squamous
cell carcinoma than in the stromal tissue samples. No statis-
tically significant differences were observed, however, for
CD56, CD57 and vimentin immunoreactivity levels of the
tumor when compared with those of the stroma.
Comparison of antigen immunoreactivity levels
in squamous cell carcinoma and the reference group
The results are presented in Table 4. Statistically significant-
ly higher MT and vimentin immunoreactivity levels were
Fig. 3 Immunoreactivity of
MT antigen (brown) in stromal
fibroblasts. Magnification 10×
(a), 40× (b). Bars50 μm
Fig. 4 a Weak MT
immunoreactivity in squamous
cell carcinoma derived from a
patient without lymph node
metastases. Magnification 10×.
Bar50 μm. b Weak MT
immunoreactivity in a patient
without lymph node metastases.
Magnification 40×. Bar50 μm
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identified in the tissue samples taken from patients with
squamous cell carcinoma than in those from the reference
group. Statistically significantly higher levels of CD56 and
CD57 antigen immunoreactivity were identified in the ref-
erence group samples than in the cancer tissue samples.
Comparison of antigen immunoreactivity levels in stroma
samples and in reference group samples
The results are presented in Table 5. Statistically signif-
icantly higher levels of immunoreactivity of MT, CD56
and CD57 antigens were observed in the reference
group samples than in stroma samples. A statistically
significantly higher level of vimentin immunoreactivity
was observed in the stroma samples than in the refer-
ence group samples.
Other comparisons
The analysis of antigen immunoreactivity levels with
respect to tumor grade and stage did not reveal any signif-
icant differences.
Statistically significantly higher MT immunoreactivity
levels within the tumor cells were identified in patients with
the presence of lymph node metastases compared with those
patients without such metastases (P<0.05).
Statistically significantly higher vimentin immunoreac-
tivity levels were observed in the tumor stroma in patients
Fig. 5 Analysis of MT
immunoreactivity. a High MT
antigen immunoreactivity in the
border part of the tumor. MT-
antigen-positive stromal
fibroblasts are also present.
Magnification 10×. b Low MT
antigen immunoreactivity in the
central part of the tumor.
Magnification 10×. c MT
antigen immunoreactivity in the
epithelial crypts of a palatine
tonsil removed because of
chronic tonsillitis.
Magnification 10×. d MT-
antigen-positive fibroblasts in
the stroma of the lymphoid
tissue in a palatine tonsil
removed because of chronic
tonsillitis. Magnification 40×.
Bars50 μm
Fig. 6 a, b Intense vimentin
immunoreactivity in both the
squamous cell carcinoma tissue
(arrows) and stromal tissue
(stars). Well-demonstrated
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with advanced tumor size (T3, T4; P<0.05). No statistically
significant differences were observed in other analyzed anti-
gens with respect to tumor size.
Discussion
The MT immunoreactivity levels were statistically signifi-
cantly higher in the tissue samples from squamous cell
carcinoma than in the reference group samples and also
higher in the tissue samples from squamous cell carcinoma
compared with the stromal samples. Moreover, the stromal
fibroblasts exhibited high vimentin and MT immunoreactiv-
ity levels. The remodeling of the tumor microenvironment
involves all of the tissue adjacent to the tumor and affects
both the cells and the extra-cellular matrix and the pattern of
expressed proteins. The new pattern of expressed proteins
and the transition from the epithelial to mesenchymal phe-
notype of cells enable the local and general dissemination of
the tumor (Dutsch-Wicherek et al. 2005, 2010; Vered et al.
2009; Paccione et al. 2008; Powell et al. 1999). In the
present study, the immunoreactivity of vimentin presented
an interesting pattern of staining and was strongly expressed
within the tumor and its septal architecture. Moreover, the
immunoreactivity level of the vimentin antigen in the stroma
increased in proportion to the T stage and was significantly
higher in the tumor itself than in the stroma. This differs
from results that we found in our previous study concerning
adenocarcinoma tissue samples and vimentin expression,
where the level of vimentin expression was higher in the
stroma than in the tumor and the septal architecture of the
tumor was not observed (Dutsch-Wicherek et al. 2010). We
did not observe any relationship between the vimentin im-
munoreactivity in the squamous cell carcinoma cells and the
clinicopathological variables; however, in oral squamous
cell carcinoma, vimentin was predominantly expressed by
cells showing a higher degree of malignancy (Satelli and Li
2011; de Araujo et al. 1993).
Similar to our previous reports, we observed the hetero-
geneity of antigens immunoreactivity within the tumor
(Jozwicki et al. 2011). MT immunoreactivity was deter-
mined in both the tumor center and in the tumor front (the
younger part of the tumor with signs of dynamic growth),
being significantly higher in the tumor front than in the
tumor center. This pattern of expression was similar to that
described in other reports with higher expression in the
border parts of the tumor and lower expression in the center
of the cancer, which is also typified by higher numbers of
apoptotic cells, a small number of fibroblasts and the pres-
ence of single macrophages (Jayasurya et al. 2000; Sundelin
Fig. 7 Immunoreactivity of vimentin antigen with positive fibroblasts
in the stroma of squamous cell carcinoma. Magnification 40×. Bar
50 μm
Table 3 Comparison of immunoreactivity levels of antigens analyzed
in squamous cell carcinoma and stroma samples (MT metallothionein,
NS not significant)
Antigen Squamous cell carcinoma Stroma P-value
Median (Q3–Q1) Median (Q3–Q1)
CD56 0 (0) 0 (0) NS
CD57 0 (1) 0 (0) NS
MT 2 (2) 0 (0) <0.0001
Vimentin 1 (1) 0 (1) <0.01
Table 4 Comparison of antigen immunoreactivity levels between
tissue samples from squamous cell carcinoma and the reference group,
namely chronic tonsillitis epithelia (MT metallothionein)
Antigen Squamous cell carcinoma Reference group P-value
Median (Q3–Q1) Median (Q3–Q1)
CD56 0 (0) 1.5 (2) <0.001
CD57 0 (1) 2.4 (3) <0.001
MT 2 (2) 0.1 (0) <0.01
Vimentin 1 (1) 0 (0) <0.001
Table 5 Comparison of CD56, CD57, metallothionein (MT) and
vimentin antigens in stroma samples and the reference group, namely
epithelia of chronic tonsillitis
Antigen Stroma Reference group P value
Median (Q3–Q1) Median (Q3–Q1)
CD56 0 (0) 1.5 (2) <0.001
CD57 0 (0) 2.4 (3) <0.001
MT 0 (0) 0.1 (0) <0.001
Vimentin 0 (1) 0 (0) <0.001
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et al. 1997; Dutsch-Wicherek et al. 2005). This particular
pattern of MT immunoreactivity has been linked to the
degree of tumor cell apoptosis (Fas expression). The higher
MT expression in the peripheral parts of the tumor has been
associated with a reduced number of tumor cells undergoing
apoptosis (resulting from MT anti-apoptotic activity) and, at
the same time, has been correlated with a higher rate of
tumor cell proliferation. Furthermore, the center of the
tumor has been found to consist in cancer cells undergoing
apoptosis and to show low MT expression (Jayasurya et al.
2000; Sundelin et al. 1997).
As mentioned above, the MT immunoreactivity levels in
the present study were significantly higher in the tissue sam-
ples from squamous cell carcinoma than in the stroma sam-
ples. The presence of MT immunoreactivity in the stroma is
intriguing in itself given that this protein has been found in
healthy epithelial cells in which it is responsible for epithelial
renewal (Dutsch-Wicherek et al. 2005; Popiela et al. 2006;
Hellquist 1997). The expression of MT by the stroma raises
the question of the real function of this protein in tumor
development. In our earlier reports concerningMTexpression
in cancer and its stroma, we suggested that MT expression
might be evoked by the chronic inflammatory process devel-
oping in the tumor as a protective mechanism (resistance to
apoptosis) of healthy adjacent cells against immune-mediated
apoptosis (Dutsch-Wicherek et al. 2005; Popiela et al. 2006).
Here, MT immunoreactivity in the stroma was present in the
fibroblasts. Cancer-associated fibroblasts play an important
role in tumor remodeling and so the MT-positive fibroblasts
showing strong vimentin immunoreactivity in the stroma
seem to be an important part of the remodeled stroma enabling
tumor spread. In the reference group, MT immunoreactivity
was observed in the epithelia of the tonsillar crypts of palatine
tonsils, whereas in the lymphatic tissue of palatine tonsils, it
was observed in the fibroblasts (Fig. 5). Since MT protects the
cell against apoptosis and enables proliferation, it is probably
a marker of tumor microenvironment remodeling. Addition-
ally, by inhibiting cytotoxic lymphocytes and stimulating the
migration of lymphocytes (Sundelin et al. 1997; Yin et al.
2005), MT plays an immunoregulatory role. Borghesi et al.
(1996) have speculated that extracellular MT interacts with
lymphocyte cellular membranes, modulating their activity,
whereas Canpolat and Lynes (2001) have also postulated an
important immunomodulating role for MT.
In the present study, we have observed that the MT immu-
noreactivity level in the cells of squamous cell carcinoma was
statistically significantly higher in patients with the presence
of lymph node metastases than in patients without such me-
tastases and this agrees with our earlier findings (Dutsch-
Wicherek et al. 2005). We did not, however, observe this
correlation in the adenocarcinoma tissue samples (Dutsch-
Wicherek et al. 2010). Our findings would seem to confirm
that MT expression correlates with poor prognostic factors.
The number of CD56- and CD57-antigen-positive lympho-
cytes identified in the tissue samples both from squamous cell
carcinoma and from the stroma was statistically significantly
lower than that in the reference group in the present study. No
differences were however seen in the number of CD56+ and
CD57+ lymphocytes between the tumor and the stroma. The
level of anti-cancer response in our study, as shown by the
CD56- and CD57-expressing lymphocytes, seemed to remain
at a comparable level in both the tumor and its stroma. All of
these findings indicate a lack of anti-cancer immune response
in squamous cell carcinoma and in the stroma and confirm the
suppressive profile of the tumor microenvironment as repre-
sented by the deficit of CD56 and CD57 effector cells.
In conclusion, MT expression by tumor cells is associated
with an aggressive phenotype of the tumor and its ability to
create metastases.
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